Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Símbolo de cotizaciónCODX
Nombre de la empresaCo-Diagnostics Inc
Fecha de salida a bolsaJul 12, 2017
Director ejecutivoMr. Dwight H. Egan
Número de empleados132
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 12
Dirección2401 S. Foothill Dr. Suite D
CiudadSALT LAKE CITY
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal84109
Teléfono18014381036
Sitio Webhttp://codiagnostics.com/
Símbolo de cotizaciónCODX
Fecha de salida a bolsaJul 12, 2017
Director ejecutivoMr. Dwight H. Egan
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos